Literature DB >> 17039602

A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Hua-Xin Liao1, Laura L Sutherland, Shi-Mao Xia, Mary E Brock, Richard M Scearce, Stacie Vanleeuwen, S Munir Alam, Mildred McAdams, Eric A Weaver, Zenaido Camacho, Ben-Jiang Ma, Yingying Li, Julie M Decker, Gary J Nabel, David C Montefiori, Beatrice H Hahn, Bette T Korber, Feng Gao, Barton F Haynes.   

Abstract

HIV-1 subtype C is the most common HIV-1 group M subtype in Africa and many parts of Asia. However, to date HIV-1 vaccine candidate immunogens have not induced potent and broadly neutralizing antibodies against subtype C primary isolates. We have used a centralized gene strategy to address HIV-1 diversity and generated a group M consensus envelope gene with shortened consensus variable loops (CON-S) for comparative studies with wild-type (WT) Env immunogens. Our results indicate that the consensus HIV-1 group M CON-S Env elicited cross-subtype neutralizing antibodies of similar or greater breadth and titer than the WT Envs tested, indicating the utility of a centralized gene strategy. Our study also shows the feasibility of iterative improvements in Env immunogenicity by rational design of centralized genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17039602      PMCID: PMC1762135          DOI: 10.1016/j.virol.2006.04.043

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  56 in total

1.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Authors:  Alexandra Trkola; Herbert Kuster; Peter Rusert; Beda Joos; Marek Fischer; Christine Leemann; Amapola Manrique; Michael Huber; Manuela Rehr; Annette Oxenius; Rainer Weber; Gabriela Stiegler; Brigitta Vcelar; Hermann Katinger; Leonardo Aceto; Huldrych F Günthard
Journal:  Nat Med       Date:  2005-05-08       Impact factor: 53.440

4.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.

Authors:  B Poon; J F Hsu; V Gudeman; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 6.  Application of the polyvalent approach to HIV-1 vaccine development.

Authors:  Julia L Hurwitz; Karen S Slobod; Tim D Lockey; Shixia Wang; Te-Hui W Chou; Shan Lu
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

7.  Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.

Authors:  Sang-Moo Kang; Fu Shi Quan; Chunzi Huang; Lizheng Guo; Ling Ye; Chinglai Yang; Richard W Compans
Journal:  Virology       Date:  2005-01-05       Impact factor: 3.616

8.  Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.

Authors:  Bhavna Chohan; Dorothy Lang; Manish Sagar; Bette Korber; Ludo Lavreys; Barbra Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

9.  Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.

Authors:  Michael S Seaman; Ling Xu; Kristin Beaudry; Kristi L Martin; Margaret H Beddall; Ayako Miura; Anna Sambor; Bimal K Chakrabarti; Yue Huang; Robert Bailer; Richard A Koup; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.

Authors:  N A Doria-Rose; G H Learn; A G Rodrigo; D C Nickle; F Li; M Mahalanabis; M T Hensel; S McLaughlin; P F Edmonson; D Montefiori; S W Barnett; N L Haigwood; J I Mullins
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more
  140 in total

1.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Authors:  Yu Feng; Krisha McKee; Karen Tran; Sijy O'Dell; Stephen D Schmidt; Adhuna Phogat; Mattias N Forsell; Gunilla B Karlsson Hedestam; John R Mascola; Richard T Wyatt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

2.  HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.

Authors:  Yuge Wang; Pratibha Kapoor; Robert Parks; Aaron Silva-Sanchez; S Munir Alam; Laurent Verkoczy; Hua-Xin Liao; Yingxin Zhuang; Peter Burrows; Michael Levinson; Ada Elgavish; Xiangqin Cui; Barton F Haynes; Harry Schroeder
Journal:  Immunogenetics       Date:  2015-12-19       Impact factor: 2.846

Review 3.  Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships.

Authors:  John F Cipollo; Lisa M Parsons
Journal:  Mass Spectrom Rev       Date:  2020-04-29       Impact factor: 10.946

4.  Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis.

Authors:  Jae-Sung Yu; James W Peacock; Stacie Vanleeuwen; Tsungda Hsu; William R Jacobs; Mark J Cayabyab; Norman L Letvin; Richard Frothingham; Herman F Staats; Hua-Xin Liao; Barton F Haynes
Journal:  Clin Vaccine Immunol       Date:  2006-08-30

5.  Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.

Authors:  Bao-Zhong Wang; Weimin Liu; Sang-Moo Kang; Munir Alam; Chunzi Huang; Ling Ye; Yuliang Sun; Yingying Li; Denise L Kothe; Peter Pushko; Terje Dokland; Barton F Haynes; Gale Smith; Beatrice H Hahn; Richard W Compans
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

Review 6.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

7.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

8.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

9.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

10.  Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein.

Authors:  Janet Irungu; Eden P Go; Ying Zhang; Dilusha S Dalpathado; Hua-Xin Liao; Barton F Haynes; Heather Desaire
Journal:  J Am Soc Mass Spectrom       Date:  2008-05-24       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.